137 related articles for article (PubMed ID: 10647913)
1. Pharmacokinetics of oligodeoxynucleotides encapsulated in liposomes: effect of lipid composition and preparation method.
Aliño SF; Crespo J; Tarrasón G; Blaya C; Adán J; Escrig E; Benet M; Crespo A; Peris JE; Piulats J
Xenobiotica; 1999 Dec; 29(12):1283-91. PubMed ID: 10647913
[TBL] [Abstract][Full Text] [Related]
2. Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting.
Ko YT; Bhattacharya R; Bickel U
J Control Release; 2009 Feb; 133(3):230-7. PubMed ID: 19013203
[TBL] [Abstract][Full Text] [Related]
3. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles.
Wilson KD; Raney SG; Sekirov L; Chikh G; deJong SD; Cullis PR; Tam YK
Int Immunopharmacol; 2007 Aug; 7(8):1064-75. PubMed ID: 17570323
[TBL] [Abstract][Full Text] [Related]
4. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes.
Li WM; Bally MB; Schutze-Redelmeier MP
Vaccine; 2001 Oct; 20(1-2):148-57. PubMed ID: 11567759
[TBL] [Abstract][Full Text] [Related]
5. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.
Mui B; Raney SG; Semple SC; Hope MJ
J Pharmacol Exp Ther; 2001 Sep; 298(3):1185-92. PubMed ID: 11504819
[TBL] [Abstract][Full Text] [Related]
6. Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN.
Tafaghodi M; Jaafari MR; Sajadi Tabassi SA
Eur J Pharm Biopharm; 2006 Oct; 64(2):138-45. PubMed ID: 16797952
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection.
Soni PN; Brown D; Saffie R; Savage K; Moore D; Gregoriadis G; Dusheiko GM
Hepatology; 1998 Nov; 28(5):1402-10. PubMed ID: 9794928
[TBL] [Abstract][Full Text] [Related]
8. The effect of circulation lifetime and drug-to-lipid ratio of intravenously administered lipid nanoparticles on the biodistribution and immunostimulatory activity of encapsulated CpG-ODN.
Raney SG; Wilson KD; Sekirov L; Chikh G; de Jong SD; Cullis PR; Tam YK
J Drug Target; 2008 Aug; 16(7):564-77. PubMed ID: 18686126
[TBL] [Abstract][Full Text] [Related]
9. Improved systemic pharmacokinetics, biodistribution, and antitumor activity of CpG oligodeoxynucleotides complexed to endogenous antibodies in vivo.
Palma E; Cho MJ
J Control Release; 2007 Jul; 120(1-2):95-103. PubMed ID: 17509715
[TBL] [Abstract][Full Text] [Related]
10. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures.
Semple SC; Klimuk SK; Harasym TO; Dos Santos N; Ansell SM; Wong KF; Maurer N; Stark H; Cullis PR; Hope MJ; Scherrer P
Biochim Biophys Acta; 2001 Feb; 1510(1-2):152-66. PubMed ID: 11342155
[TBL] [Abstract][Full Text] [Related]
11. Liposome-encapsulated midazolam for oral administration.
Tomoyasu Y; Yasuda T; Maeda S; Higuchi H; Miyawaki T
J Liposome Res; 2011 Jun; 21(2):166-72. PubMed ID: 20684674
[TBL] [Abstract][Full Text] [Related]
12. Constant pressure-controlled extrusion method for the preparation of Nano-sized lipid vesicles.
Morton LA; Saludes JP; Yin H
J Vis Exp; 2012 Jun; (64):. PubMed ID: 22760481
[TBL] [Abstract][Full Text] [Related]
13. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines.
Joseph A; Louria-Hayon I; Plis-Finarov A; Zeira E; Zakay-Rones Z; Raz E; Hayashi T; Takabayashi K; Barenholz Y; Kedar E
Vaccine; 2002 Sep; 20(27-28):3342-54. PubMed ID: 12213404
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of separation of non-encapsulated drug from unilamellar liposomes by various methods.
Dipali SR; Kulkarni SB; Betageri GV
J Pharm Pharmacol; 1996 Nov; 48(11):1112-5. PubMed ID: 8961156
[TBL] [Abstract][Full Text] [Related]
15. Liposomal CpG-ODN: An in vitro and in vivo study on macrophage subtypes responses, biodistribution and subsequent therapeutic efficacy in mice models of cancers.
Nikoofal-Sahlabadi S; Matbou Riahi M; Sadri K; Badiee A; Nikpoor AR; Jaafari MR
Eur J Pharm Sci; 2018 Jul; 119():159-170. PubMed ID: 29660463
[TBL] [Abstract][Full Text] [Related]
16. Modeling cytoplasmic release of encapsulated oligonucleotides from cationic liposomes.
Tamaddon AM; Shirazi FH; Moghimi HR
Int J Pharm; 2007 May; 336(1):174-82. PubMed ID: 17196349
[TBL] [Abstract][Full Text] [Related]
17. Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy.
Wilson KD; de Jong SD; Tam YK
Adv Drug Deliv Rev; 2009 Mar; 61(3):233-42. PubMed ID: 19232375
[TBL] [Abstract][Full Text] [Related]
18. Rapid plasma clearance and metabolism in vivo of a phosphorothioate oligodeoxynucleotide with a single, internal phosphodiester bond.
Boado RJ; Kang YS; Wu D; Pardridge WM
Drug Metab Dispos; 1995 Nov; 23(11):1297-300. PubMed ID: 8591734
[No Abstract] [Full Text] [Related]
19. Development of efficient packaging method of oligodeoxynucleotides by a condensed nano particle in lipid envelope structure.
Yamada Y; Kogure K; Nakamura Y; Inoue K; Akita H; Nagatsugi F; Sasaki S; Suhara T; Harashima H
Biol Pharm Bull; 2005 Oct; 28(10):1939-42. PubMed ID: 16204950
[TBL] [Abstract][Full Text] [Related]
20. Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo.
Gokhale PC; McRae D; Monia BP; Bagg A; Rahman A; Dritschilo A; Kasid U
Antisense Nucleic Acid Drug Dev; 1999 Apr; 9(2):191-201. PubMed ID: 10355825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
